Black Box Warning on CSL's Injectafer Unlikely to Change Much
Dow Jones07:34
2329 GMT [Dow Jones]--The addition of a black box warning to the label of CSL's Injectafer is unlikely to have a big impact, according to Citi. The Food and Drug Administration approved revised labeling for the iron replacement medicine to warn of the risk of low levels of phosphate in the blood. "We do not think it will change much," says Citi. "Generics to Injectafer have become available over the last few weeks and, per FDA, are expected to update their labels also." Citi has a neutral rating and A$160/share target on CSL. The stock ended Wednesday at A$173.85.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments